NL-OMON46940
Completed
Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis - AMAC
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- inflamatory bowel disease
- Sponsor
- Eli Lilly and Company
- Enrollment
- 7
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •This study will include male or female subjects \>\=18 and \<\=75 years of age with moderate to severe active UC (defined as a Mayo score of 6 to 12 with an endoscopic subscore \>\=2\).
Exclusion Criteria
- •This study will include male or female subjects \>\=18 and \<\=75 years of age with moderate to severe active UC (defined as a Mayo score of 6 to 12 with an endoscopic subscore \>\=2\).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosism (ALS)Motor Neuron Disease10029317NL-OMON45879Cytokinetics, Inc.11
Completed
Phase 2
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial HypercholesterolemiaNL-OMON45499Madrigal Pharmaceuticals, Inc.24
Completed
Phase 2
A Phase 2b Multicentre, Randomised, Double-Blind, Active Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2NL-OMON52170Astra Zeneca9
Completed
Phase 2
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)NL-OMON50318ReveraGen BioPharma, Inc.7
Recruiting
Phase 2
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetesType 1 diabetesDiabetes10018424NL-OMON49006Diamyd Medical AB2